TY - JOUR
T1 - Successful outcome with reduced-intensity condition regimen followed by allogeneic hematopoietic stem cell transplantation for relapsed or refractory anaplastic large-cell lymphoma
AU - Fukano, Reiji
AU - Mori, Tetsuya
AU - Fujita, Naoto
AU - Kobayashi, Ryoji
AU - Mitsui, Tetsuo
AU - Kato, Koji
AU - Suzuki, Ritsuro
AU - Suzumiya, Junji
AU - Fukuda, Takahiro
AU - Shindo, Motohiro
AU - Maseki, Nobuo
AU - Shimoyama, Tatsu
AU - Okada, Keiko
AU - Inoue, Masami
AU - Inagaki, Jiro
AU - Hashii, Yoshiko
AU - Sato, Atsushi
AU - Tabuchi, Ken
N1 - Funding Information:
We wish to thank each of the clinicians, hospital administrators, and health center administrators who provided precise data via the registry of the Japan Society for Stem Cell Transplantation. We also wish to thank Yuki Yamashita for supporting the data analysis.
Publisher Copyright:
© 2019, Japanese Society of Hematology.
PY - 2019/12/1
Y1 - 2019/12/1
N2 - We report a retrospective analysis of 38 patients (age ≤ 30 years) who underwent allogeneic hematopoietic stem cell transplantation (allo-SCT) for relapsed or refractory anaplastic large-cell lymphoma (ALCL). Median follow-up for survivors after undergoing allo-SCT was 72 months (range, 35–96 months). Eight patients received reduced-intensity conditioning (RIC) regimens, including three patients with fludarabine plus melphalan-based regimens and five patients with fludarabine plus busulfan-based regimens. The remaining 30 patients received myeloablative conditioning (MAC) regimens. Median ages in the RIC and MAC groups were 24 and 15 years, respectively. The 5-year overall survival rates in the RIC and MAC groups were 100% and 49%, respectively (P = 0.018). The 5-year event-free survival rates in the RIC and MAC groups were 88% and 43%, respectively (P = 0.039). In the RIC group, four of the eight patients showed residual disease at allo-SCT, but all eight patients survived with complete remission (CR), including one patient with relapse. This result suggests that allo-SCT using the RIC regimen may be effective for relapsed or refractory ALCL in children, adolescents, and young adults, even in non-CR cases.
AB - We report a retrospective analysis of 38 patients (age ≤ 30 years) who underwent allogeneic hematopoietic stem cell transplantation (allo-SCT) for relapsed or refractory anaplastic large-cell lymphoma (ALCL). Median follow-up for survivors after undergoing allo-SCT was 72 months (range, 35–96 months). Eight patients received reduced-intensity conditioning (RIC) regimens, including three patients with fludarabine plus melphalan-based regimens and five patients with fludarabine plus busulfan-based regimens. The remaining 30 patients received myeloablative conditioning (MAC) regimens. Median ages in the RIC and MAC groups were 24 and 15 years, respectively. The 5-year overall survival rates in the RIC and MAC groups were 100% and 49%, respectively (P = 0.018). The 5-year event-free survival rates in the RIC and MAC groups were 88% and 43%, respectively (P = 0.039). In the RIC group, four of the eight patients showed residual disease at allo-SCT, but all eight patients survived with complete remission (CR), including one patient with relapse. This result suggests that allo-SCT using the RIC regimen may be effective for relapsed or refractory ALCL in children, adolescents, and young adults, even in non-CR cases.
UR - http://www.scopus.com/inward/record.url?scp=85073964209&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073964209&partnerID=8YFLogxK
U2 - 10.1007/s12185-019-02748-1
DO - 10.1007/s12185-019-02748-1
M3 - Article
C2 - 31620968
AN - SCOPUS:85073964209
SN - 0925-5710
VL - 110
SP - 723
EP - 728
JO - International journal of hematology
JF - International journal of hematology
IS - 6
ER -